Novartis reportedly knew of discrepancies in the Zolgensma data it had submitted to the FDA but delayed informing regulators so has announced alterations to its processes.
List view / Grid view
Filter the results
The pharmaceutical company failed to inform the FDA of manipulated data when the gene therapy was under review and could face a legal battle.
The FDA has given approval to AveXis for the first treatment of paediatric spinal muscular atrophy (SMA).